Active and clinically significant bacterial, fungal, or viral infection
Active and clinically significant bacterial, fungal, or viral infection
Active and clinically significant bacterial, fungal, or viral infection
Evidence of other clinically significant uncontrolled condition(s) including, but not limited to, uncontrolled systemic infection (viral, bacterial, or fungal)
Any clinically significant infection defined as any acute viral, bacterial, or fungal infection that requires specific treatment. NOTE: Anti-infective treatment must be completed ? 7 days prior to study registration.
Exhibits evidence of other clinically significant uncontrolled condition(s), including, but not limited to: uncontrolled systemic infection (viral, bacterial, or fungal), diagnosis of fever and neutropenia within 1 week prior to first dose of study drug.
Participant exhibits evidence of other clinically significant uncontrolled systemic infection requiring therapy (viral, bacterial or fungal).
have any clinically significant infection, defined as any acute viral, bacterial, or fungal infection that requires systemic treatment or have received any anti-infective treatment within 7 days prior to the screening visit;
Participant exhibits evidence of other clinically significant uncontrolled systemic infection requiring therapy (viral, bacterial or fungal).
Afebrile with clear chest imaging and no signs of active viral, bacterial, fungal infection unless determined to be, at the discretion of the investigator, not clinically significant in the context of this study
Clinically significant active viral, bacterial or fungal infection requiring:
Clinically significant active viral, bacterial or fungal infection
Current unresolved infection or history of chronic, active, clinically significant infection (viral, bacterial, fungal, or other) which, in the opinion of the Investigator, would preclude the patient from exposure to a biologic agent or pose a risk to patient safety
Current or recent history (< 21 days prior to start of treatment) of a clinically significant bacterial, viral, fungal, parasitic or mycobacterial infection
Has any clinically significant infection, i.e., any acute viral, bacterial, or fungal infection that requires specific treatment (anti-infective treatment has to be completed ? 7 days prior to study entry).
Any clinically significant infection defined as any acute viral, bacterial, or fungal infection that requires specific treatment. NOTE: Anti-infective treatment must be completed ? 7 days prior to study registration.
Participant exhibits evidence of other clinically significant uncontrolled condition(s) including, but not limited to: uncontrolled systemic infection requiring IV therapy (viral, bacterial or fungal).
Other clinically significant uncontrolled condition(s) including, but not limited to, systemic infection (viral, bacterial or fungal)
Active and clinically significant bacterial, fungal, or viral infection
Exhibits evidence of other clinically significant uncontrolled condition(s), including, but not limited to: uncontrolled systemic infection (viral, bacterial, or fungal), diagnosis of fever and neutropenia within 1 week prior to first dose of study drug
Active and clinically significant bacterial, fungal, or viral infection
Active and clinically significant bacterial, fungal or viral infection
Subject exhibits evidence of other clinically significant uncontrolled condition(s) including, but not limited to:\r\n* Active systemic fungal infection\r\n* Diagnosis of fever and neutropenia within 1 week prior to study drug administration
Chronic myelomonocytic leukemia or myelodysplastic/myeloproliferative neoplasm (unacceptable MDS subtypes); uncontrolled bacterial, viral or fungal infection (currently taking medication and with progression or no clinical improvement) at time of enrollment.
Current uncontrolled bacterial, viral or fungal infection (currently taking medication with evidence of progression of clinical symptoms or radiologic findings).
Patients with uncontrolled bacterial, viral or fungal infections (currently taking medication and with progression or no clinical improvement) at time of enrollment.
Uncontrolled bacterial, viral, or fungal infection at the time of enrollment. Uncontrolled is defined as currently taking medication and with progression or no clinical improvement on adequate medical treatment.
Current uncontrolled bacterial, viral or fungal infection (currently taking medication with evidence of progression of clinical symptoms or radiologic findings); the principal investigator is the final arbiter of this criterion
Uncontrolled bacterial, fungal or viral infections with progression of clinical symptoms despite therapy
Current uncontrolled bacterial, fungal or viral infections (defined as currently taking medication and having continuing clinical symptoms or radiologic findings)
Uncontrolled bacterial, viral, or fungal infection at the time of enrollment; uncontrolled is defined as currently taking medication and with progression or no clinical improvement on adequate medical treatment
Uncontrolled bacterial, viral or fungal infection defined as currently taking medication and progression of clinical symptoms
Current uncontrolled bacterial, viral or fungal infection (currently taking medication with evidence of progression of clinical symptoms or radiologic findings)
Evidence of uncontrolled bacterial, viral, or fungal infections (currently taking medication and progression of clinical symptoms) within one month prior to starting the conditioning regimen
Current uncontrolled bacterial, viral or fungal infection (currently taking medication with evidence of progression of clinical symptoms or radiologic findings)
Patients with uncontrolled bacterial, viral or fungal infections (currently taking medication and progression of clinical symptoms).
Uncontrolled bacterial, viral or fungal infection defined as currently taking antimicrobial therapy and progression of clinical symptoms
No current uncontrolled bacterial, viral or fungal infection (defined as currently taking medication and progression of clinical symptoms)
Uncontrolled bacterial, viral, or fungal infection (currently taking medication and with progression or no clinical improvement)
Uncontrolled viral, bacterial, or fungal infections (currently taking medication and with progression of clinical symptoms or findings); patients with symptoms consistent with respiratory syncytial virus (RSV), influenza A, B, or parainfluenza at the time of enrollment will be assayed for the above viruses and if positive are not eligible for the trial until they are no longer symptomatic (patients may have continued assay positivity for a period of time post resolution of symptoms secondary to the nature of the assay)
Patients with uncontrolled bacterial, viral or fungal infections (currently taking medication and progression of clinical symptoms)
Current uncontrolled bacterial, viral or fungal infection (currently taking medication with evidence of progression of clinical symptoms or radiologic findings)
Uncontrolled bacterial, viral or fungal infections (i.e., currently taking medications with progression of clinical symptoms or signs)
Uncontrolled bacterial, viral or fungal infection (currently taking medication and with progression or no clinical improvement).
Uncontrolled bacterial, viral or fungal infections (currently taking medication and progression of clinical symptoms)
Patients with uncontrolled bacteria, viral or fungal infections (currently taking medication and progression of clinical symptoms)
Patients with uncontrolled bacterial, viral or fungal infections (currently taking medication and with progression or no clinical improvement) at time of enrollment
Currently uncontrolled bacterial, viral, or fungal infection (progression of clinical symptoms despite therapy);
Patients with uncontrolled bacterial, viral or final infections (currently taking medication ad with progression or no clinical improvement) at time of enrollment
No uncontrolled bacterial, viral or fungal infection at time of enrollment defined as currently taking medication and progression of clinical symptoms
Current uncontrolled bacterial, viral or fungal infection (currently taking medication with evidence of progression of clinical symptoms or radiologic findings).
Patients with uncontrolled bacterial, viral or fungal infections (currently taking medication and with progression or no clinical improvement) at time of enrollment
Patients with uncontrolled bacterial, viral or fungal infections (currently taking medication and with progression or no clinical improvement) at time of enrollment.
REGISTRATION STEP 2-RANDOMIZATION: Patients must not have active infection (systemic bacterial, fungal, or viral infection) that is not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement despite appropriate antibiotics or other treatment)
Patients must not have systemic fungal, bacterial, viral or other infection that is not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment)
Patients must not have a systemic bacterial, fungal, or viral infection that is not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement despite appropriate antibiotics or other treatment)
Uncontrolled systemic fungal, bacterial, viral, or other serious infection (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment); may be enrolled if controlled on treatment
Patients with a systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment)
Presence of a systemic fungal, bacterial, viral or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment).
Patients with a systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment)
Subject has an untreated or uncontrolled infection defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy and/or other treatment.
Uncontrolled and active systemic fungal, bacterial, viral, or other infection (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment).
Uncontrolled active systemic fungal, bacterial, viral, or other infection (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment), or intravenous anti infective treatment within 2 weeks before first dose of study drug.
Uncontrolled systemic fungal, bacterial or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy and/or other treatment)
Patient with uncontrolled systemic fungal, bacterial, viral or other infection with ongoing signs/symptoms despite appropriate treatment
Patients with systemic fungal, bacterial, viral or other infection that is exhibiting ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics or other treatment
Patients with a systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment)
Patients with a systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment)
Systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment)
Uncontrolled systemic fungal, bacterial, viral, or other infection (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment)
Systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment)
Have an active, uncontrolled, systemic fungal, bacterial, or viral infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment.
Subject has an uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment).
Uncontrolled intercurrent illness including, but not limited to, ongoing or active systemic fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics or other treatment), uncontrolled hypertension, cardiac arrhythmia, pneumonitis, interstitial lung disease, active peptic ulcer disease or gastritis that would limit compliance with study requirement.
Patients must not have a systemic fungal, bacterial, viral or other infection that is not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment)
Active uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment)
Uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment)
Patients with a systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment)
Uncontrolled active systemic fungal, bacterial, viral, or other infection (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment), or intravenous anti-infective treatment within 2 weeks before first dose of study drug
Systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment)
Uncontrolled systemic fungal, bacterial, viral, or other infection (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment)
Systemic fungal, bacterial, viral, or other infection if not controlled; defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment (may be enrolled if controlled on treatment)
Systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment)
Patients will be excluded if they have a systemic fungal, bacterial, viral or other infection of which they exhibit ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics or other treatment; the patient needs to be off all pressor medications and have negative blood cultures for at least 48 hours
Uncontrolled active systemic fungal, bacterial, viral, or other infection (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment)
Patients will be excluded if they have a systemic fungal, bacterial, viral or other infection that is exhibiting ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics or other treatment.
Systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment)
Patients will be excluded if they have a systemic fungal, bacterial, viral or other infection that is exhibiting ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics or other treatment.
Subject has an active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy, defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment.
Participant with a systemic fungal, bacterial, viral or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement), despite appropriate antibiotics or other treatment)
Systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment)
Specifically diagnosed and uncontrolled fungal, bacterial, viral, or other infection (e.g. confirmed sepsis, pneumonia, abscess, cellulitis, etc.) at the day chemotherapy is initiated. \Uncontrolled\ is defined as exhibiting ongoing signs and symptoms of infection without improvement despite antimicrobial or other treatment.
Uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment)
Uncontrolled systemic fungal, bacterial or viral infection at time of enrollment (defined as ongoing signs/symptoms related the infection without improvement despite appropriate antibiotics, antiviral therapy and/or other treatment).
Known active bacterial, viral, fungal, mycobacterial, or other infection
Ongoing treatment for systemic bacterial, fungal, or viral infection at Screening
Presence of fungal, bacterial, viral, or other infection requiring oral or IV antimicrobials for management within 7 days of first dose AMG 757
Symptomatic/active bacterial, or fungal, or any other opportunistic infection
Uncontrolled bacterial, viral or fungal infection in the 6 weeks before enrollment.
Known uncontrolled fungal, bacterial, and/or viral infection ?Grade 2.
Active bacterial, fungal or viral infection
Systemic fungal, bacterial, viral or other infection that is not controlled.
Current active, uncontrolled bacterial, viral, or fungal infection
Active bacterial or viral infection
Evidence of an ongoing systemic bacterial, fungal, or viral infection.
Participants with active viral, bacterial or fungal infection requiring concurrent antiviral or antibiotics
Active >= grade 3 viral, bacterial, or fungal infection within 2 weeks prior to day 1 of protocol therapy
Active bacterial, fungal, or viral infection
PROCUREMENT EXCLUSION: Active bacterial fungal or viral infection
TREATMENT EXCLUSION: Active bacterial, viral or fungal infection
Systemic fungal, bacterial, viral or other infection that is not controlled
Active invasive fungal infection requiring treatment with anti-fungal medication
Active uncontrolled acute fungal, bacterial, or other infection that is unresponsive to therapy at time of study drug dosing
Have an active fungal, bacterial, and/or known viral infection
Uncontrolled viral or bacterial infection at the time of study enrollment
AUTOLOGOUS APHERESIS: Severe intercurrent bacterial, viral or fungal infection
TREATMENT WITH SJCAR19: Severe, uncontrolled bacterial, viral or fungal infection
Subjects with uncontrolled systemic fungal, bacterial, viral or other infection despite appropriate antibiotics or other treatment at the time of leukapheresis or during day 0 (within 24 hrs of CAR T infusion)
Having any uncontrolled illness including ongoing or active bacterial, viral or fungal infection
Presence of fungal, bacterial, viral, or other infection requiring IV antimicrobials for management within 7 days of enrollment. Note: Simple UTI and uncomplicated bacterial pharyngitis are permitted if responding to active treatment and after consultation with sponsor.
Any active grade 3 or higher (per NCI CTCAE version 4.03) viral, bacterial, or fungal infection within 2 weeks of the first dose of the study drug. Routine antimicrobial prophylaxis is permitted.
Currently receiving systemic antimicrobial treatment for active infection (viral, bacterial, or fungal) at the time of first dose of enfortumab vedotin. Routine antimicrobial prophylaxis is permitted.
Presence of fungal, bacterial, viral, or other infection that is uncontrolled or requiring IV antimicrobials for management.
Active bacterial, fungal or viral infection.
Subjects with uncontrolled systemic fungal, bacterial, viral or other infection despite appropriate antibiotics or other treatment at the time of leukapheresis
Uncontrolled bacterial, viral or fungal infection in the 6 week before enrollment
Known uncontrolled fungal, bacterial, and/or viral infection ?Grade 2
Active viral, bacterial, or fungal infection progressing on current treatment
Active bacterial, fungal or viral infection not controlled by adequate treatment, at enrollment.
Active bacterial, fungal or viral infection not controlled by adequate treatment, at enrollment
Patients with uncontrolled systemic fungal, bacterial, viral or other infection are ineligible
Presence of fungal, bacterial, viral, or other infection requiring IV antimicrobials for management. Note: Simple urinary tract infection (UTI) and uncomplicated bacterial pharyngitis are permitted if responding to active treatment.
Ongoing or active infection (bacterial, fungal, or viral) of National Cancer Institute (NCI)-CTCAE version 4.03 grade > 2
Presence of fungal, bacterial, viral, or other infection that is uncontrolled or requiring intravenous antimicrobials for management.
Uncontrolled systemic fungal, bacterial, viral, or other infection
Active systemic fungal, bacterial, viral, or other infection, unless disease is under treatment with anti-microbials and/or controlled or stable; patients with fever thought to be likely secondary to leukemia are eligible; known hypersensitivity to any study drug
Documented fungal infection within 3 months of BMT
Active bacterial, fungal or viral infection
Patients with uncontrolled active infection (viral, bacterial, and fungal) are not eligible
Active >= grade 3 (per NCI CTCAE v4) viral, bacterial, or fungal infection within 2 weeks prior to initiation of study treatment
Does not have current uncontrolled bacterial, fungal, or viral infection
Uncontrolled active systemic infection (viral, bacterial, and fungal)
Acute bacterial, viral, or fungal infection requiring treatment at the time of registration
Active uncontrolled systemic fungal, bacterial or viral infection
uncontrolled infection including evidence of ongoing systemic bacterial, fungal, or viral infection (excluding viral upper respiratory tract infections) at the time of initiation of study treatment;
Uncontrolled active systemic infection (viral, bacterial, and fungal)
Active bacterial, fungal or viral infection including hepatitis B (HBV), hepatitis C (HCV) , requiring treatment with intravenous (IV) antibiotic, IV anti-fungal, or anti-viral; (testing is not required for eligibility)
Uncontrolled viral, fungal, or bacterial infection
REGORAFENIB EXCLUSION CRITERIA: Known active infection (bacterial, fungal, viral); viral infection includes known HIV positivity, or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapy
ENTRECTINIB EXCLUSION CRITERIA: Known active infection (bacterial, fungal, viral including HIV positivity)
Active systemic fungal, bacterial, viral or other infection, unless disease is under treatment with antimicrobials and considered controlled in the opinion of the investigator
Active serious systemic disease, including active bacterial or fungal infection
Active viral, fungal, bacterial or other infection
Active fungal infection or bacterial sepsis
Patients should not have any uncontrolled illness including ongoing or active bacterial, viral or fungal infection
Patients must not have an uncontrolled bacterial, fungal or viral infection, defined as progressive symptoms despite therapy, at the time of the CD8+ memory T-cell infusion; asymptomatic viremia is allowed
Patients with uncontrolled active infection (viral, bacterial, and fungal) are not eligible
Patients with documented active bacterial, viral or fungal infection, untreated systematic peptic ulcer disease, uncontrolled diabetes mellitus or serious concurrent medical disease that could limit survival to less than 3 months
PART 2: Uncontrolled viral or bacterial infection at the time of study enrollment
An uncontrolled bacterial, viral, or fungal infection or an active duodenal ulcer, until these conditions are corrected or controlled.
Does not have current uncontrolled bacterial, fungal, or viral infection
Known mixed invasive mold fungal infection including Zygomycetes, and/or a known invasive Aspergillus fungal infection in which either study drug may not be considered active.
Active uncontrolled bacterial, viral, or fungal infection until these conditions are corrected or controlled
Uncontrolled viral, bacterial or fungal infection
Uncontrolled bacterial, mycobacterial, or fungal infection
Active ongoing viral, bacterial, or fungal infection
Active viral, bacterial or fungal infection unless adequately treated; for fungal infection, patient should have completed full course of antifungal therapy with resolution of infection
Active viral, bacterial or fungal infection
Uncontrolled viral or bacterial infection at the time of study enrollment
Uncontrolled viral or bacterial infection at the time of study enrollment
Active fungal, bacterial, and/or viral infection.
Other serious uncontrolled conditions such as fungal, bacterial or viral infection; HIV, Hepatitis B or C, bleeding disorders, interstitial lung disease,
Patients with known NCI CTCAE Grade 3 or higher (requiring IV antibiotics) active systemic or cutaneous viral, bacterial, or fungal infection.
Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of enrollment
Active systemic fungal, bacterial, and/or viral infection.
Any active viral, bacterial, or systemic fungal infection within 4 weeks prior study entry
216 Presence of fungal, bacterial, viral, or other infection requiring IV antimicrobials for management within 7 days of first dose AMG 562. NOTE: Simple UTI and uncomplicated bacterial pharyngitis are permitted after consultation with sponsor and if responding to active treatment.
Uncontrolled systemic fungal, bacterial, viral or other infection despite appropriate antibiotics or other treatment at the time of leukapheresis or lisocabtagene maraleucel administration
Acute viral, bacterial, or fungal infection, which requires specific therapy. Acute therapy must have been completed at least 7 days prior to study treatment.
Uncontrolled active systemic fungal, bacterial, viral, or other infection or requirement for intravenous (IV) antibiotics
Presence of fungal, bacterial, viral, or other infection requiring IV antimicrobials for management\r\n* Note: Simple urinary tract infection (UTI) and uncomplicated bacterial pharyngitis are permitted if responding to active treatment
Uncontrolled viral or bacterial infection at the time of study enrollment
Participant had a serious infection within 2 weeks prior to randomization, including any Grade 3 or higher viral, bacterial, or fungal infection.
Evidence of active viral, bacterial, or systemic fungal infection.
Patients with a systemic fungal, bacterial, viral, or other infection not controlled
Active bacterial, viral, or fungal infection
Serious concomitant disorder, including active bacterial, fungal, or viral infection, incompatible with the study (at the discretion of the principal investigator)
Any active grade 3 or higher (per NCI CTCAE version 4.03) viral, bacterial, or fungal infection within 2 weeks of the first dose of the study drug. Routine antimicrobial prophylaxis is permitted.
Has an invasive fungal infection.
active bacterial, fungal infection, or detectable viral infection
Uncontrolled acute life threatening bacterial, viral or fungal infection (e.g. blood culture positive ? 72 hours prior to infusion)
Uncontrolled acute life threatening bacterial, viral or fungal infection
Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of start of study drug
Uncontrolled systemic fungal, bacterial, or viral infection
Have active bacterial, fungal, and/or known viral infection.
Active bacterial infection
Active bacterial, viral, fungal, or other infection
Serious systemic fungal, bacterial, viral, or other infection that is not controlled or requires intravenous antibiotics
Progressive or persistent viral or bacterial infection
Active bacterial infection
Patients with a history of active systemic fungal infection.
Presence of fungal, bacterial, viral, or other infection that is uncontrolled or requiring IV antimicrobials for management.
Patients with uncontrolled active infection (viral, bacterial, and fungal) are not eligible
Any history of current or within the past 48 hours of acute or chronic bacterial, fungal or viral infectious disease
Have active bacterial or fungal infection, or detectable viral infection
Have an active infection of any kind (fungal, viral, or bacterial)
Systemic fungal, bacterial, viral, or other infection that is not controlled
Uncontrolled bacterial, viral or fungal infection
Active viral, bacterial or fungal infection
Patients with a systemic fungal, bacterial, viral, or other infection not controlled despite appropriate antibiotics or other treatment; uncontrolled systemic infections require infectious disease consultation for verification
Uncontrolled viral or bacterial infection at the time of study enrollment
Uncontrolled viral, bacteria or fungal infection at time of study enrollment
Subjects with acute infection: any acute viral, bacterial, or fungal infection which requires specific therapy; acute therapy must have been completed more than 14 days prior to study treatment
Active viral, bacterial or fungal infection
Active bacterial or viral infection
Active fungal, bacterial, and/or viral infection
Active viral, bacterial or fungal infection
Uncontrolled systemic bacterial, fungal or viral infection
The participant has active bacterial infection, fungal infection, or detectable viral infection or viral load.
Patients with other conditions not related to leukemic relapse (e.g. veno-occlusive disease or uncontrolled bacterial, viral or invasive fungal infection) which are also life-threatening and which would preclude evaluation of the effects of a T cell infusion
Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of enrollment
Systemic fungal, bacterial, viral, or other infection that is not controlled, at the time of screening
Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of randomization
Fungal or viral infection requiring additional therapy
Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of enrollment
Have an active, known fungal, bacterial, and/or known viral infection.
Current uncontrolled bacterial, viral or fungal infection.
Have an active infection of any kind (fungal, viral, or bacterial)
Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of enrollment
Active bacterial, fungal or viral infection.
Have an active, known fungal, bacterial, and/or known viral infection.
Presence of fungal, bacterial, viral, or other infection that is uncontrolled or requiring IV antimicrobials for management. Simple UTI and uncomplicated bacterial pharyngitis are permitted if responding to active treatment
Active symptomatic fungal, bacterial and/or viral infection including evidence of infection with HIV, HTL, positive serology for HCV or HBV (acute or chronic infection based on CDC guidelines)
Have a known active fungal, bacterial, and/or known viral infection. Hepatocellular cancer participants with chronic viral (B or C) hepatitis are eligible if they retain adequate liver function.
Viral, bacterial, or fungal infection within 2 weeks prior to the first dose of treatment.
Evidence of uncontrolled systemic bacterial, fungal, or viral infection at the start of study drug
Active viral, bacterial or fungal infection requiring intravenous treatment with antimicrobial therapy starting less than four weeks prior to first dose.
Active bacterial, viral, or fungal infection
Does not have current uncontrolled bacterial, fungal, or viral infection
Patient has a current uncontrolled bacterial, fungal, or viral infection per the judgment of the principal investigator (PI)
Active systemic fungal, bacterial, viral, or other infection, unless under treatment with anti-microbials and controlled/stable, as defined as being afebrile and hemodynamically stable for 24-48 hours
Active uncontrolled bacteria, fungal or viral infection
Does not have current uncontrolled bacterial, fungal, or viral infection per the judgment of the principal investigator (PI)
Active bacterial infection
Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection
Patients with uncontrolled active infection (viral, bacterial, and fungal) are not eligible
Evidence of any viral, bacterial, or fungal infection involving the lung and not responding to appropriate treatment
Active infection (symptomatic bacterial and fungal infection – newly diagnosed and/or requiring treatment)
Patients with a documented active infection prior to starting their preparative regimen; this includes grade 3 or higher viral, bacterial, or fungal infection
Patients with a documented active infection prior to starting their preparative regimen; this includes grade 3 or higher viral, bacterial, or fungal infection
Patients with a documented active infection prior to starting their preparative regimen; this includes grade 3 or higher viral, bacterial, or fungal infection
Uncontrolled viral, bacterial, fungal or protozoal infection at the time of study enrollment
Uncontrolled bacterial, viral infection or invasive fungal infection
Active bacterial, viral, fungal infection not controlled with appropriate antimicrobial therapy
Subjects who are being treated for fungal, viral, or bacterial pneumonia
Uncontrolled bacterial, viral or fungal infection at the time of leukapheresis, lymphodepleting chemotherapy or JCAR017 infusion
Respiratory illness of a bacterial or viral etiology within 30 days of MRI
Presence of fungal, bacterial, viral, or other infection requiring IV antimicrobials for management.
Invasive bacterial infection
Active serious systemic disease, including active bacterial or fungal infection within 2 weeks before study entry
Patients with active bacterial or fungal infections unresponsive to medical therapy
Active bacterial or systemic viral or fungal infections
Known active infections (bacterial, fungal, viral including HIV positivity).
Active bacterial infections.
Active viral or bacterial infections: this includes any infections that are being actively treated even if the signs and symptoms appear to have resolved. Courses of antibiotics or anti-viral treatment should be completed before the patient is enrolled
Ongoing systemic bacterial, fungal, or viral infection (including upper respiratory tract infections)
HIV or active bacterial, viral or fungal infections
Evidence of an ongoing systemic bacterial, fungal, or viral infection (including upper respiratory tract infections) at the time of start of voruciclib therapy
Evidence of an ongoing systemic bacterial, fungal, or viral infection (including upper respiratory tract infections) at the time of start of study therapy. Note: Subjects with localized fungal infections of skin or nails are not precluded from participation.
Patients with any active and uncontrolled infections (such as bacterial, fungal, and new or reactivated viral infections)
Active bacterial or fungal infections unresponsive to medical therapy
Uncontrolled active infections (viral, bacterial, and fungal)
Severe infections ? 4 weeks prior to enrolment in the study as well as active, uncontrolled bacterial, viral or fungal infections requiring systemic treatment.
Active uncontrolled bacterial, fungal, or viral infections – all prior infections must have resolved following optimal therapy
Evidence of an ongoing systemic bacterial, fungal, or viral infection (including upper respiratory tract infections) at the time of start of study therapy. Note: Subjects with localized fungal infections of skin or nails are eligible.
Patients with uncontrolled bacterial, viral or fungal infections
Active bacterial, fungal or viral infections unresponsive to medical therapy
Subjects who have uncontrolled infection are not eligible; patients must have any active infections under control; fungal disease must be stable for at least 2 weeks before study entry
Active uncontrolled bacterial, viral or fungal infections
Uncontrolled active infections (viral, bacterial, and fungal); the study chair will be the final arbiter of this criterion
Patients with uncontrolled active infections (viral, bacterial, or fungal) are not eligible
PART 1: Uncontrolled viral, bacterial, or fungal infections at the time of study enrollment
Patients with active uncontrolled bacterial, viral or fungal infections (undergoing appropriate treatment and with progression of clinical symptoms)
Uncontrolled viral, bacterial, or fungal infections
Active uncontrolled bacterial, viral or fungal infections
Active bacterial, viral or fungal infections
Uncontrolled bacterial, viral or fungal infections.
Subject has active viral or bacterial infections or any coexisting medical problem that would significantly increase the risks of this treatment program.
Active, uncontrolled urogenital bacterial, viral or fungal infections, including urinary tract infection (UTI). Skin/nail fungal infections are not exclusionary. Subjects with active shingles (varicella zoster infection) will be excluded from the study.
Subjects who have uncontrolled infection are not eligible; patients must have any active infections under control; fungal disease must be stable for at least 2 weeks before study entry
Active bacterial or fungal infection; all prior infections must be resolved following optimal therapy
Active bacterial, fungal, or viral infections – all prior infections must have resolved following optimal therapy
Known active infections (bacterial, fungal, viral including HIV positivity).
Patients with active bacterial or fungal infections unresponsive to medical therapy
Active, uncontrolled bacterial, viral, or fungal infections.
Active bacterial or systemic viral or fungal infections.
Ongoing systemic bacterial, fungal, or viral infections at the time of initiation of study treatment.
Subjects who have uncontrolled infection are not eligible; patients must have any active infections under control; fungal disease must be stable for at least 2 weeks before study entry
Active bacterial, viral or fungal infections
Active bacterial or fungal infections unresponsive to medical therapy
Active viral or bacterial infections or any coexisting medical problem that would significantly increase the risks of this treatment program.
Active bacterial, fungal or viral infections requiring treatment with intravenous (IV) antibiotic, IV antifungal, or IV anti-viral drugs
Patients with acute infections (viral, bacterial or fungal infections requiring therapy)
Active bacterial or fungal infections unresponsive to medical therapy
Active infections (bacterial, fungal, or viral)
Ongoing systemic bacterial, fungal or viral infection (with the exception of fungal infections of the skin or nails).
Active uncontrolled bacterial, viral or fungal infections.
Uncontrolled bacterial, viral, or fungal infections
Patients with uncontrolled active infections (viral, bacterial, and fungal are not eligible)
Evidence of ongoing systemic bacterial, fungal, or viral infection (excluding viral upper respiratory tract infections) at the time of initiation of study treatment
Patients with uncontrolled active infections (viral, bacterial, and fungal) are not eligible
Patients with active fungal, viral, or bacterial infections
Patients with uncontrolled active infections (viral, bacterial, and fungal are not eligible)
Acute infections (viral, bacterial or fungal infections requiring therapy).
Any history of recent serious bacterial, viral, fungal, or other opportunistic infections, precluding a stem cell transplant according to the treating physician
Active uncontrolled bacterial or invasive fungal infections
Active, uncontrolled urogenital bacterial, viral or fungal infections, including urinary tract infection that in the opinion of the investigator, contraindicates participation. Skin/nail fungal infections are not exclusionary. Subjects with active shingles (varicella zoster infection) will be excluded from the study.
Uncontrolled bacterial, viral or fungal infections
Active uncontrolled bacterial, fungal, or viral infections – all prior infections must have resolved following optimal therapy
Patients with invasive fungal infections
Subjects with active fungal, viral, or bacterial infections.
Evidence of any serious bacterial, viral, parasitic or systemic fungal infections within the 30 days prior to study entry
Evidence of any active, uncontrolled bacterial, viral, parasitic fungal infections within 1 week of first dose of study drug
Evidence of active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 7 days prior to the initiation of study drug.
Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
COHORT 1: Has an active uncontrolled infection requiring systemic therapy (viral, bacterial or fungal); patients with infection under active treatment and controlled with antibiotics are eligible
COHORT 2: Has an active uncontrolled infection requiring systemic therapy (viral, bacterial or fungal); patients with infection under active treatment and controlled with antibiotics are eligible
Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
Active bacterial, viral, or fungal infection requiring systemic therapy.
Active bacterial, fungal, or viral infection requiring systemic treatment; patients who are receiving treatment for infections that are under control may be included in this study
Active, uncontrolled bacterial, viral, or fungal infections, within 7 days of study entry requiring systemic therapy.
Active, uncontrolled bacterial, viral, or fungal infections, within 7 days of study entry requiring systemic therapy.
Patients with active, uncontrolled bacterial, viral or fungal infection(s) requiring systemic therapy
Active, uncontrolled bacterial, viral, fungal, or other opportunistic infection requiring systemic therapy.
Subjects with active or uncontrolled bacterial, viral, or fungal infections requiring systemic therapy
Active systemic viral, bacterial or fungal infection requiring treatment
Subject exhibits evidence of uncontrolled systemic infection requiring therapy (viral, bacterial or fungal)
Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
Active bacterial or fungal infections requiring systemic treatment within 7 days of treatment
Active bacterial or viral infections requiring systemic therapy
Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
Active bacterial, viral, or fungal infections, requiring systemic therapy apart from anti-viral maintenance therapy for HIV.
Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
Active, uncontrolled bacterial, viral or fungal infection, requiring systemic therapy
Patient has active and uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
Active bacterial, viral, or fungal infection requiring systemic therapy or operative or radiological intervention.
Patients with active viral, bacterial or systemic fungal infection requiring treatment.
Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
Have active, bacterial, viral, or fungal infections, requiring systemic therapy
Patients with active or uncontrolled bacterial, viral, or fungal infections requiring systemic therapy
Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy.
Active systemic viral, bacterial or fungal infections requiring treatment.
Active, uncontrolled bacterial, viral, or fungal infection requiring systemic therapy
Subject has active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy.
Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy.
Active viral, bacterial, or systemic fungal infection requiring parenteral treatment within four weeks of enrollment. Patients requiring any oral antiviral, fungal, or bacterial therapy must have completed treatment within one week of enrollment.
Active bacterial, viral, or fungal infection requiring systemic treatment at the time of study entry.
Active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 7 days of first study drug administration
Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
Presence of known active bacterial, fungal, or viral infection requiring systemic therapy
Participants with active bacterial, viral, or fungal infection requiring systemic treatment
Participants with active bacterial, viral, or fungal infection requiring systemic treatment within the last two months prior to registration
Active, uncontrolled bacterial, viral or fungal infection requiring systemic therapy.
Patient has active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy.
Any active systemic infection (viral, fungal, or bacterial) requiring active parenteral antibiotic therapy within 4 weeks of study drug administration.
Any active systemic viral, bacterial, or fungal infection requiring IV treatment with antimicrobial therapy within 1 week prior to first dose
Patient has active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy.
Active, uncontrolled bacterial, viral, or fungal infection requiring systemic therapy at time of screening.
Subject has active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy.
Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
Evidence of uncontrolled, active infection, requiring systemic anti-bacterial, anti-viral or anti-fungal therapy ? 7 days prior to administration of study medication
Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
Active, uncontrolled bacterial, viral, or fungal infections requiring systemic therapy.
Patient has active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
Patient has active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
Subject has serious/active bacterial, viral or fungal infection requiring systemic treatment.
Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy.
History of active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 14 days
Active, uncontrolled bacterial, viral, or fungal infections, including urinary tract infection, within 7 days of study entry requiring systemic therapy
Active, uncontrolled bacterial, viral, or fungal infections requiring systemic therapy
Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
Patients with active or uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
Active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 7 days of first study drug administration
Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
Active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 7 days prior to the initiation of study drug.
